The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 12, pp. 1593-1598. DOI 10.1345/aph.10365
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Messmer, K.
Right arrow Articles by Abel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Messmer, K.
Right arrow Articles by Abel, S.

Research Articles

Verteporfin for age-related macular degeneration

KJ Messmer and SR Abel

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug-drug interactions, and the therapeutic issues concerning the use of verteporfin in patients with age-related macular degeneration (AMD). DATA SOURCES: Published articles and abstracts in English were identified by MEDLINE (1990-August 2000) searches using the search terms verteporfin, treatment of age-related macular degeneration, and photodynamic therapy (PDT). Additional references were identified from the bibliographies of the retrieved articles. Data were also obtained from approved product labeling. DATA EXTRACTION: The literature was assessed for adequate description of patients, methodology, and outcomes. DATA SYNTHESIS: Verteporfin is a synthetic benzoporphyrin derivative and a cytotoxic photosensitizing agent, which is one component of PDT. PDT involves administration of verteporfin for injection and nonthermal red light at a wavelength of 689 nm. It is metabolized, to a small extent, to its diacid metabolite by liver and plasma esterases. Information concerning drug interactions is limited. In clinical trials, verteporfin was effective in patients with wet AMD as demonstrated in standard visual acuity scores. Adverse events were related to injection site reactions and visual disturbances. CONCLUSIONS: Verteporfin is a welcome alternative to laser photocoagulation, which can result in damage to the retina and lead to visual loss. Although long-term trials have not been performed in humans, results from monkeys indicate possible improvement in vision following PDT with verteporfin.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. Schattner and A. Pollack
Verteporfin and myocardial infarction
Ann. Pharmacother., February 1, 2004; 38(2): 352 - 352.
[Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
J F Jordan, M Diestelhorst, S Grisanti, and G K Krieglstein
Photodynamic modulation of wound healing in glaucoma filtration surgery
Br. J. Ophthalmol., July 1, 2003; 87(7): 870 - 875.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.